Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Sarcoma 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neurilemmoma 1Neoplasm Metastasis 1Meningioma 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × HDAC-42 × Clear all
NCT02282917 2025-12-05

Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

Massachusetts Eye and Ear Infirmary

Phase EARLY_PHASE1 Terminated
7 enrolled 19 charts
CNS

Meningioma, Neurilemmoma, Neuroma, Acoustic, Neurofibromatosis 2

NCT02795819 2019-10-24

Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

Virginia Commonwealth University

Phase 1 Terminated
6 enrolled 12 charts
GenitourinarySarcoma

Carcinoma, Renal Cell, Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡